Mesenchymal stem or stromal cells from amnion and umbilical cord tissue and their potential for clinical applications
- PMID: 24710543
- PMCID: PMC3901122
- DOI: 10.3390/cells1041061
Mesenchymal stem or stromal cells from amnion and umbilical cord tissue and their potential for clinical applications
Abstract
Mesenchymal stem or stromal cells (MSC) have proven to offer great promise for cell-based therapies and tissue engineering applications, as these cells are capable of extensive self-renewal and display a multilineage differentiation potential. Furthermore, MSC were shown to exhibit immunomodulatory properties and display supportive functions through parakrine effects. Besides bone marrow (BM), still today the most common source of MSC, these cells were found to be present in a variety of postnatal and extraembryonic tissues and organs as well as in a large variety of fetal tissues. Over the last decade, the human umbilical cord and human amnion have been found to be a rich and valuable source of MSC that is bio-equivalent to BM-MSC. Since these tissues are discarded after birth, the cells are easily accessible without ethical concerns.
Figures
Similar articles
-
Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton's jelly and umbilical cord.Intern Med J. 2013 Apr;43(4):430-9. doi: 10.1111/imj.12044. Intern Med J. 2013. PMID: 23176558
-
Canine placenta: A promising potential source of highly proliferative and immunomodulatory mesenchymal stromal cells?Vet Immunol Immunopathol. 2016 Mar;171:47-55. doi: 10.1016/j.vetimm.2016.02.005. Epub 2016 Feb 11. Vet Immunol Immunopathol. 2016. PMID: 26964717
-
Mesenchymal stromal cells derived from human umbilical cord tissues: primitive cells with potential for clinical and tissue engineering applications.Adv Biochem Eng Biotechnol. 2010;123:29-54. doi: 10.1007/10_2009_15. Adv Biochem Eng Biotechnol. 2010. PMID: 20012739
-
Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications.Curr Stem Cell Res Ther. 2013 Mar;8(2):144-55. doi: 10.2174/1574888x11308020005. Curr Stem Cell Res Ther. 2013. PMID: 23279098 Review.
-
Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies?Tissue Eng Part B Rev. 2014 Oct;20(5):523-44. doi: 10.1089/ten.TEB.2013.0664. Epub 2014 Apr 22. Tissue Eng Part B Rev. 2014. PMID: 24552279 Review.
Cited by
-
Stem Cell-Based Therapy for Asherman Syndrome: Promises and Challenges.Cell Transplant. 2021 Jan-Dec;30:9636897211020734. doi: 10.1177/09636897211020734. Cell Transplant. 2021. PMID: 34105392 Free PMC article. Review.
-
Comparative evaluation of mesenchymal stromal cells from umbilical cord and amniotic membrane in xeno-free conditions.BMC Cell Biol. 2018 Dec 13;19(1):27. doi: 10.1186/s12860-018-0178-8. BMC Cell Biol. 2018. PMID: 30545286 Free PMC article.
-
Stem cell-based regenerative medicine.Stem Cell Investig. 2019 Jul 18;6:19. doi: 10.21037/sci.2019.06.04. eCollection 2019. Stem Cell Investig. 2019. PMID: 31463312 Free PMC article. Review.
-
Innovative Strategies for Liver Transplantation: The Role of Mesenchymal Stem Cells and Their Cell-Free Derivatives.Cells. 2024 Sep 25;13(19):1604. doi: 10.3390/cells13191604. Cells. 2024. PMID: 39404368 Free PMC article. Review.
-
Enhancement of acellular cartilage matrix scaffold by Wharton's jelly mesenchymal stem cell-derived exosomes to promote osteochondral regeneration.Bioact Mater. 2021 Feb 13;6(9):2711-2728. doi: 10.1016/j.bioactmat.2021.01.031. eCollection 2021 Sep. Bioact Mater. 2021. PMID: 33665503 Free PMC article.
References
-
- Alviano F., Fossati V., Marchionni C., Arpinati M., Bonsi L., Franchina M., Lanzoni G., Cantoni S., Cavallini C., Bianchi F., et al. Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro. BMC. Dev. Biol. 2007;7:11. doi: 10.1186/1471-213X-7-11. - DOI - PMC - PubMed
-
- Diaz-Prado S., Muinos-Lopez E., Hermida-Gomez T., Cicione C., Rendal-Vazquez M.E., Fuentes-Boquete I., de Toro F.J., Blanco F.J. Human amniotic membrane as an alternative source of stem cells for regenerative medicine. Differentiation. 2011;81:162–171. doi: 10.1016/j.diff.2011.01.005. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources